Text Size

Study of Atenolol Influence on Blood Pressure During Resistance Exercise

This study has been completed.
Sponsor:
Collaborator:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Information provided by:
University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT01030016
First received: December 8, 2009
Last updated: December 14, 2009
Last verified: May 2009
History of Changes
  Purpose

The study was designed to investigate if atenolol is able to blunt blood pressure increase during resistance exercise in hypertensive subjects.


Condition Intervention Phase
Blood Pressure
Exercise
 Drug: atenolol
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Supportive Care
Official Title: Blood Pressure Response During Resistance Exercise in Hypertensives: Influence of Beta-blockers

Resource links provided by NLM:

Drug Information available for: Atenolol
U.S. FDA Resources

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • blood pressure during resistance exercise [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Enrollment: 10
Study Start Date: May 2007
Study Completion Date: May 2009
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: atenolol
subjects received 6 weeks of atenolol
 Drug: atenolol
25 mg/day, twice a day for 6 weeks
Other Name: beta-blockers

Detailed Description:

The study compared intra-arterial blood pressure responses during leg-extension resistance exercise performed to fatigue at 40, 80 and 100% of 1 RM in hypertensive patients receiving placebo (first) and atenolol (second) on a single blind manner.

  Eligibility

Ages Eligible for Study:   30 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • hypertension with blood pressure levels below 160/105 mmHg under placebo.
  • age between 30 and 60 years
  • nonobese

Exclusion Criteria:

  • target organ lesion
  • cardiovascular risk factor
  • cardiovascular disease
  • physically active
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01030016

Locations
Brazil
University of São Paulo
São Paulo, Brazil, 05508030
Sponsors and Collaborators
University of Sao Paulo
Fundação de Amparo à Pesquisa do Estado de São Paulo
Investigators
Principal Investigator: Cláudia LM Forjaz, PhD University of São Paulo
Study Chair: Decio Mion Jr, PhD University of São Paulo
  More Information

No publications provided

Responsible Party: Cláudia Lúcia de Moraes Forjaz, School of Physical Education and Sport, University of São Paulo
ClinicalTrials.gov Identifier: NCT01030016     History of Changes
Other Study ID Numbers: FAPESP-06/06356-8
Study First Received: December 8, 2009
Last Updated: December 14, 2009
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by University of Sao Paulo:
resistance exercise
beta-blockers
blood pressure

Additional relevant MeSH terms:
Adrenergic beta-Antagonists
Atenolol
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
 Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
Antihypertensive Agents
Sympatholytics
Autonomic Agents
Peripheral Nervous System Agents
Adrenergic beta-1 Receptor Antagonists

ClinicalTrials.gov processed this record on June 17, 2013